Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics Inc.

An update from Dynagreen Environmental Protection Group Co., Ltd. Class H ( ($HK:1330) ) is now available. Dynagreen Environmental Protection Group...

Dynagreen’s Shareholders Approve Key Resolutions at 2025 EGM

Palladyne AI Corp ( ($PDYN) ) just unveiled an update. On November 17, 2025, Palladyne AI Corp released an investor presentation outlining its stra...

Palladyne AI Corp Unveils Defense-Focused Transformation

Dynatronics ( ($DYNT) ) has released a notification of late filing. Dynatronics Corporation has announced a delay in filing its Form 10-Q (Quarter ...

Dynatronics Delays Form 10-Q Filing

Oppenheimer analyst Andreas Argyrides maintained a Hold rating on Dyne Therapeutics today and set a price target of $11.00. Argyrides covers the He...

Dyne Therapeutics (DYN) Gets a Hold from Oppenheimer

Grid Dynamics Holdings, Inc. (GDYN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Grid Dynamics Holdings, Inc. faces ...

Grid Dynamics Faces Investor Scrutiny as Executives Plan Major Stock Sales

Grid Dynamics Holdings, Inc. (($GDYN)) has held its Q3 earnings call. Read on for the main highlights of the call. Grid Dynamics Holdings, Inc. rec...

Grid Dynamics Reports Record Revenue Amid Mixed Sentiment

Grid Dynamics Holdings, Inc. ( ($GDYN) ) has released its Q3 earnings. Here is a breakdown of the information Grid Dynamics Holdings, Inc. presente...

Grid Dynamics Reports Record Q3 2025 Revenues

Grid Dynamics Holdings ( ($GDYN) ) just unveiled an announcement. On October 23, 2025, Grid Dynamics Holdings announced a $50 million share repurch...

Grid Dynamics Announces $50M Share Repurchase Program

Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Dyne Therapeutics today and set a price target of $36.00. The company’s shares clos...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DYN	$21.18	+5.27%	1.91M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DYN	$21.18	+5.3%	1.91M
3
4
5
6

DYN

DYN

Dividend Overview

Get Dyne Therapeutics Inc. Data in Excel

Get Dyne Therapeutics Inc. Data in Excel